PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis
Recruiting now · Not applicable
Conditions studied: Deep Vein Thrombosis
In brief
Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein. Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.
Key facts
- Study ID
- NCT07622199
- Run by
- RenJi Hospital
- People needed
- 140
- Starts
- 2026-06-24
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2026-07-21
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years and ≤ 85 years;
- Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and PFV (confirmed by preoperative ultrasound, CT venography, or pre-procedural venography);
- Time from symptom onset to endovascular treatment ≤ 14 days;
- Patient receives endovascular treatment with PMT;
- Patient provides written informed consent.
You may not qualify if…
- Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb;
- Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
- Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents;
- Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension;
- Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications;
- Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
- Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders;
- Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or thrombocytopenia (platelet count < 80,000/mL);
- History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
- Pregnancy;
- Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy < 24 months;
- Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study;
- Unwillingness to participate in this trial.
Where it is running
- Renji hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.